Clinical Trials

Colonic Neoplasms, Colorectal Neoplasms

NCT05064059 2025-09-17

MK-4280A-007

441 enrolled 24 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Colorectal Neoplasms

NCT04393298 2025-05-29

A Study to Assess the Safety, Pharmacokinetics and Anti Tumor Activity of UCB6114 Administered Intravenously to Participants With Advanced Solid Tumors

Phase 1/2 Completed

93 enrolled 28 charts

Advanced Solid Tumors

NCT02261532 2024-11-14

A Phase I Study of TAS-102 in Solid Tumors

15 enrolled 7 charts

Advanced or Metastatic Solid Tumors

NCT04737187 2024-09-24

SUNLIGHT

492 enrolled 22 charts 1 FDA

Colorectal Neoplasms

NCT01607957 2024-09-19

RECOURSE

800 enrolled 12 charts

Colorectal Neoplasms

NCT01867866 2024-09-05

Study Comparing the Pharmacokinetics of FTD as a Component of TAS-102 With FTD Alone

44 enrolled

Advanced Solid Tumors

NCT01867879 2024-09-05

Study to Evaluate the Cardiac Safety of TAS-102 in Patients With Advanced Solid Tumors

BreastOther solid neoplasm

44 enrolled

Advanced Solid Tumors (Excluding Breast Cancer)

NCT01874522 2024-09-05

Study Comparing the Bioavailability of TAS-102 Tablets to an Oral Solution Containing Equivalent Amounts of FTD and TPI

BreastOther solid neoplasm

46 enrolled

Advanced Solid Tumors (Excluding Breast Cancer)

NCT01916447 2024-09-05

A Phase I Study of TAS-102 in Patients With Advanced Gastrointestinal Tumors.

65 enrolled

Advanced Gastrointestinal Tumors

NCT02031055 2024-09-05

Study of the Mass Balance of Oral FTD and TPI as Components of TAS-102 in Patients With Advanced Solid Tumors

8 enrolled

Advanced Solid Tumors

NCT02301104 2024-09-05

A Phase I Study of TAS-102 in Patients With Advanced Solid Tumors With Hepatic Impairment

24 enrolled

Liver Diseases, Liver Neoplasms

NCT02301117 2024-09-05

A Phase I Study of TAS-102 in Patients With Advanced Solid Tumors With Renal Impairment

43 enrolled

Genitourinary

Carcinoma, Renal Cell, Kidney Diseases, Kidney Neoplasms, Urologic Diseases, Renal Insufficiency

NCT02500043 2024-09-03

Study of TAS-102 or Placebo Plus BSC in Patients With Metastatic Gastric Cancer

507 enrolled 17 charts 1 FDA

Stomach Neoplasms

NCT02860546 2024-09-03

A Study Evaluating TAS-102 Plus Nivolumab in Patients With MSS CRC

Phase 2 Completed

18 enrolled 12 charts

Neoplasm Metastasis, Colorectal Neoplasms

NCT03274882 2024-07-25

Study of Efficacy and Safety of S 95005 (TAS-102) in Patients With Metastatic Colorectal Cancer Who Failed Standard Chemotherapies

Phase 2 Completed

26 enrolled

Neoplasm Metastasis, Neoplasms, Colorectal Neoplasms

NCT03810742 2023-11-18

Nanoliposomal Irinotecan (Nal-IRI, ONIVYDE®) in Combination With TAS-102 (LONSURF®) in Refractory Solid Tumors

44 enrolled

Refractory Solid Tumors

NCT03616574 2022-09-21

First-in-human Study of CA102N Monotherapy and CA102N Combined With Trifluridine/Tipiracil (LONSURF) in Subjects With Advanced Solid Tumors

37 enrolled

Colorectal Neoplasms

NCT03974594 2022-04-19

Bioequivalence Study of Trifluridine and Tipiracil Tablets in Colorectal Cancer Patients

64 enrolled

Colorectal Neoplasms

NCT01955837 2020-11-17

TERRA

406 enrolled 22 charts

Colorectal Neoplasms

NCT03031691 2020-08-11

A Study of Brontictuzumab With Chemotherapy for Subjects With Previously Treated Metastatic Colorectal Cancer

7 enrolled